Matrix Metalloproteinase-28 Deletion Amplifies Inflammatory and Extracellular Matrix Responses to Cardiac Aging

Abstract To determine if matrix metalloproteinase (MMP)-28 mediates cardiac aging, wild-type (WT) and MMP-28−/− young (7 ± 1 months, n = 9 each) and old (20 ± 2 months, n = 7 each) female mice were evaluated. MMP-28 expression in the left ventricle (LV) increased 42% in old WT mice compared to young controls (p < 0.05). By Doppler echocardiography, LV function declined at 20 ± 2 months of age for both groups. However, dobutamine stress responses were similar, indicating that cardiac reserve was maintained. Plasma proteomic profiling revealed that macrophage inflammatory protein (MIP)-1 α, MIP-1β and MMP-9 plasma levels did not change in WT old mice but were significantly elevated in MMP-28−/− old mice (all p < 0.05), suggestive of a higher inflammatory status when MMP-28 is deleted. RT2-PCR gene array and immunoblotting analyses demonstrated that MIP-1α and MMP-9 gene and protein levels in the LV were also higher in MMP-28−/− old mice (all p < 0.05). Macrophage numbers in the LV increased similarly in WT and MMP-28−/− old mice, compared to respective young controls (both p < 0.05). Collagen content was not different among the WT and MMP-28−/− young and old mice. In conclusion, LV inflammation increases with age, and MMP-28 deletion further elevates inflammation and extracellular matrix responses, without altering macrophage numbers or collagen content.

[1]  W. Parks,et al.  Epilysin, a Novel Human Matrix Metalloproteinase (MMP-28) Expressed in Testis and Keratinocytes and in Response to Injury* , 2001, The Journal of Biological Chemistry.

[2]  J. Reynolds,et al.  Methamphetamine and HIV-1 gp120 Effects on Lipopolysaccharide Stimulated Matrix Metalloproteinase-9 Production by Human Monocyte-Derived Macrophages , 2011, Immunological investigations.

[3]  Y. Kihara,et al.  Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. , 2002, Journal of the American College of Cardiology.

[4]  Shyun-Yeu Liu,et al.  Functional role of matrix metalloproteinase-28 in the oral squamous cell carcinoma. , 2006, Oral oncology.

[5]  J. Keski‐Oja,et al.  Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. , 2002, The Journal of investigative dermatology.

[6]  M. Entman,et al.  Cardiac function in young and old Little mice. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  T. Betsuyaku,et al.  Epilysin (MMP-28) Restrains Early Macrophage Recruitment in Pseudomonas aeruginosa Pneumonia1 , 2009, The Journal of Immunology.

[8]  C. López-Otín,et al.  Differential Expression of Three Matrix Metalloproteinases, MMP-19, MMP-26, and MMP-28, in Normal and Inflamed Intestine and Colon Cancer , 2004, Digestive Diseases and Sciences.

[9]  Richard T. Lee,et al.  Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. , 2006, American journal of physiology. Heart and circulatory physiology.

[10]  M. Stella,et al.  Effect of in vitro mechanical compression on Epilysin (matrix metalloproteinase‐28) expression in hypertrophic scars , 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[11]  Craig J. Hartley,et al.  Pulsed Doppler signal processing for use in mice: applications , 2005, IEEE Transactions on Biomedical Engineering.

[12]  J. Keski‐Oja,et al.  Epilysin (MMP‐28) – structure, expression and potential functions , 2008, Experimental dermatology.

[13]  J. Keski‐Oja,et al.  Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells , 2006, Journal of Cell Science.

[14]  F. Spinale,et al.  Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. , 2000, Cardiovascular research.

[15]  Merry L. Lindsey,et al.  MMP Induction and Inhibition in Myocardial Infarction , 2004, Heart Failure Reviews.

[16]  M. Lindsey,et al.  Extracellular matrix remodeling following myocardial injury , 2003, Annals of medicine.

[17]  A. Dufour,et al.  Furin Functions as a Nonproteolytic Chaperone for Matrix Metalloproteinase-28: MMP-28 Propeptide Sequence Requirement , 2010, Biochemistry research international.

[18]  J. Cigarroa,et al.  CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. , 2011, American journal of physiology. Heart and circulatory physiology.

[19]  A. Strongin,et al.  MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. , 2001, Gene.

[20]  W. Parks,et al.  The mouse matrix metalloproteinase, epilysin (MMP-28), is alternatively spliced and processed by a furin-like proprotein convertase. , 2003, The Biochemical journal.

[21]  A. Parker,et al.  Expression profiling of metalloproteinases and their inhibitors in cartilage. , 2004, Arthritis and rheumatism.

[22]  Hai-Chao Han,et al.  Age-related cardiac muscle sarcopenia: Combining experimental and mathematical modeling to identify mechanisms , 2008, Experimental Gerontology.

[23]  X. Puente,et al.  Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors , 2004, Biological chemistry.

[24]  D. Bassi,et al.  Proprotein convertases: “Master switches” in the regulation of tumor growth and progression , 2005, Molecular carcinogenesis.

[25]  P. Rabinovitch,et al.  Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. , 2009, Trends in cardiovascular medicine.

[26]  Nancy A. Jenkins,et al.  GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function , 1993, Nature Genetics.

[27]  H. Putter,et al.  CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. , 2008, Journal of molecular and cellular cardiology.

[28]  N. Frangogiannis,et al.  The role of inflammatory and fibrogenic pathways in heart failure associated with aging , 2010, Heart Failure Reviews.

[29]  B. Altun,et al.  Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. , 2009, European journal of internal medicine.

[30]  N. Frangogiannis Chemokines in the ischemic myocardium: from inflammation to fibrosis , 2004, Inflammation Research.

[31]  H. Katus,et al.  Critical Role for Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1α in Induction of Experimental Autoimmune Myocarditis and Effective Anti–Monocyte Chemoattractant Protein-1 Gene Therapy , 2005, Circulation.

[32]  Sawa Kostin,et al.  Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. , 2011, International journal of cardiology.

[33]  Daniel Levy,et al.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. , 2003, Circulation.

[34]  Mayuko Nishimura,et al.  Drosophila as a model to study cardiac aging , 2011, Experimental Gerontology.

[35]  T. R. Hansen,et al.  Collagen gene expression in rat left ventricle: interactive effect of age and exercise training. , 2000, Journal of applied physiology.